DLBCL

October 27, 2017October 27, 2017

FDA Clears Way for Denovo to Launch Phase 3 Trial of DB102 for DLBCL Patients in US

News

The U.S. Food and Drug Administration (FDA) has given Denovo Biopharma the green light to advance its investigational drug DB102 into a Phase 3 clinical trial for diffuse large B-cell lymphoma ... Read more

September 28, 2017September 28, 2017

Autolus’ Trials Will Assess AUTO3 as Potential Therapy in Leukemia, Lymphoma Patients

News

Autolus has initiated two Phase 1/2 trials to test AUTO3, a new CAR T-cell therapy that targets two cancer proteins instead of one. The trials, AMELIA and ALEXANDER, will be ... Read more

September 12, 2017

Transplant Recipients Account for 3% of non-Hodgkin Lymphoma Cases in Children, Study Finds

News

Nearly three out of every 100 cases of non-Hodgkin lymphoma in American children and adolescents occurs in those who received an organ transplant, a study reports. The research showed that the ... Read more

September 1, 2017

Lymphoma Patient’s Brain Tumor Disappeared After She Received JCAR017, Study Reports

News

Juno Therapeutics‘ immunotherapy JCAR017 eliminated a brain tumor in a patient whose lymphoma had spread to her brain, researchers at Massachusetts General Hospital Cancer Center reported. The team wrote about the ... Read more

August 15, 2017August 15, 2017

New Combo Treatment for DLBCL, R-Chop Plus Acalabrutinib, Being Tested in UK

News

The University of Southampton in Britain is leading a Phase 1/2 clinical trial to test whether adding acalabrutinib to R-CHOP can improve outcomes for patients with diffuse large B-cell lymphoma (DLBCL). ... Read more

August 3, 2017

Kite Seeks EU Approval for CAR T-Cell Therapy in 3 Lymphoma Subtypes

News

Kite Pharma submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) requesting the approval of its CAR T-cell therapy, axicabtagene ciloleucel, as treatment for patients with certain ... Read more

June 28, 2017June 28, 2017

Tazemetostat Benefits Follicular and B-cell Lymphoma Patients with EZH2 Mutations, Phase 2 Trial Shows

News

Twelve of 13 patients with relapsed or refractory follicular lymphoma (FL) and mutations of the EZH2 enzyme responded either fully or partially to treatment with tazemetostat, according to a Phase 2 clinical trial. Tazemetostat, ... Read more

June 15, 2017

37% of Those Who Received CTL019 in Phase 2 Clinical Trial Had Their Lymphoma Disappear

News

Thirty-seven percent of patients with a difficult-to-treat lymphoma had their cancer disappear after receiving Novartis’ CTL019 (tisagenlecleucel), according to an interim analysis of Phase 2 clinical trial results. Other patients achieved ... Read more

June 8, 2017June 8, 2017

T-Cell Therapy JCAR017 Eliminates Tumor Cells in Half of DLBCL Patients in Phase 1 Trial

News

Recently announced data from a Phase 1 trial for investigational T-cell therapy JCAR017 shows a high response rate for patients with relapsed or refractory CD19+ aggressive B-cell non-Hodgkin lymphoma (NHL), ... Read more

May 25, 2017May 25, 2017

Karyopharm to Present New Phase 2 Data on Selinexor in Advanced DLBCL Patients

News

Karyopharm Therapeutics will soon present interim data from a Phase 2b clinical trial evaluating selinexor (KPT-330), an oral selective inhibitor of the nuclear export compound, in patients with relapsed or refractory diffuse large B-cell ... Read more